Search research articles
Contact Us
Filters
Showing results (31-40 of 99) with videos related to
Page
of 10
Sort By:
Pancreas
|
July 4, 2019
Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma
Claire Johns, Celso L Diaz, Jimmy Hwang, et al.
Journal of Gastrointestinal Oncology
|
November 19, 2020
Variability in multimodality treatment influences survival in non-metastatic gastric cancer patients
Tuyen Hoang, Farshid Dayyani, Ariceli Alfaro, et al.
AJR. American Journal of Roentgenology
|
August 7, 2020
Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma
Zhen J Wang, Ting T Zhang, Chansik An, et al.
Cancer Chemotherapy and Pharmacology
|
October 12, 2012
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
Andrew H Ko, Thach-Giao Truong, Emily Kantoff, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 17, 2007
A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer
Andrew H Ko, Jeanne M Quivey, Alan P Venook, et al.
The Oncologist
|
February 8, 2020
Clinicopathologic Characteristics and Impact of Oophorectomy for Ovarian Metastases from Colorectal Cancer
Carling Ursem, Margaret Zhou, Alan Paciorek, et al.
Pancreas
|
June 13, 2022
The Additional Diagnostic Benefit of Pancreatic Cancer Molecular Profiling After Germline Testing
Evan J Walker, Amie M Blanco, Julia Carnevale, et al.
Familial Cancer
|
September 30, 2018
Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma
Evan J Walker, Julia Carnevale, Christina Pedley, et al.
Molecular Cancer Therapeutics
|
August 7, 2013
Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma
Olga K Mirzoeva, Eric A Collisson, Peter M Schaefer, et al.
Investigational New Drugs
|
March 20, 2016
A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers
Andrew L Coveler, Andrew H Ko, Daniel V T Catenacci, et al.
Page
of 10
Search research articles
Search
Showing results (31-40 of 99) with videos related to
Sort By:
Page
of 10
Pancreas
|
July 4, 2019
Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma
Claire Johns, Celso L Diaz, Jimmy Hwang, et al.
Journal of Gastrointestinal Oncology
|
November 19, 2020
Variability in multimodality treatment influences survival in non-metastatic gastric cancer patients
Tuyen Hoang, Farshid Dayyani, Ariceli Alfaro, et al.
AJR. American Journal of Roentgenology
|
August 7, 2020
Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma
Zhen J Wang, Ting T Zhang, Chansik An, et al.
Cancer Chemotherapy and Pharmacology
|
October 12, 2012
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
Andrew H Ko, Thach-Giao Truong, Emily Kantoff, et al.
International Journal of Radiation Oncology, Biology, Physics
|
March 17, 2007
A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer
Andrew H Ko, Jeanne M Quivey, Alan P Venook, et al.
The Oncologist
|
February 8, 2020
Clinicopathologic Characteristics and Impact of Oophorectomy for Ovarian Metastases from Colorectal Cancer
Carling Ursem, Margaret Zhou, Alan Paciorek, et al.
Pancreas
|
June 13, 2022
The Additional Diagnostic Benefit of Pancreatic Cancer Molecular Profiling After Germline Testing
Evan J Walker, Amie M Blanco, Julia Carnevale, et al.
Familial Cancer
|
September 30, 2018
Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma
Evan J Walker, Julia Carnevale, Christina Pedley, et al.
Molecular Cancer Therapeutics
|
August 7, 2013
Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma
Olga K Mirzoeva, Eric A Collisson, Peter M Schaefer, et al.
Investigational New Drugs
|
March 20, 2016
A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers
Andrew L Coveler, Andrew H Ko, Daniel V T Catenacci, et al.
Page
of 10